Bicycle Therapeutics plc
Moat Score — Bicycle Therapeutics plc
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Proprietary bicyclic-peptide chemistry platform and phage-display screening technology are patent-protected and have attracted multiple major pharma partnerships, but the value is unproven absent approved products. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | No manufacturing scale or cost edge; the company outsources all production to CDMOs and has no cost structure advantage over peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | No commercial products exist yet, so there is no demonstrated pricing power; any future pricing would face payer/reimbursement negotiation like any oncology drug. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A biotech drug-discovery platform has no network effect; value does not increase with more users or partners in a self-reinforcing way. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Existing collaboration partners (Genentech, Novartis, Bayer, Ionis) have sunk R&D investment in specific programs, creating modest switching friction, but partners can and do walk away from underperforming assets. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The company operates in a niche modality (bicyclic peptides) that limits direct competition today, but this reflects platform novelty rather than a defensible efficient-scale barrier. |